Search results for " Myocardial infarction"

showing 10 items of 247 documents

Exploring the association between extra-cardiac troponin elevations and risk of future mortality

2019

Although the measurement of cardiac troponin I (cTnI) and T (cTnT) has now become the cornerstone for diagnosing cardiac injury, both ischemic and non-ischemic, recent evidence has become available that many patients display extra-cardiac causes of cTn elevations and carry a considerably enhanced risk of future mortality. The current literature data suggests that cTn elevations may be equally common in patients with cardiac and extra-cardiac diseases. Among the latter cohort of patients, the leading extra-cardiac diseases which may be responsible for either cTnI or cTnT elevations include infectious diseases/sepsis, pulmonary disorders, renal failure, malignancy, as well as gastrointestinal…

030213 general clinical medicinemedicine.medical_specialtycardiac injuryClinical Biochemistry030209 endocrinology & metabolismSepsislcsh:Biochemistry03 medical and health sciences0302 clinical medicineTroponin complexInternal medicineTroponin IOpinion Papermedicinelcsh:QD415-436Myocardial infarctionStrokeCause of deathbiologybusiness.industrytroponinBiochemistry (medical)medicine.diseaseTroponinmortalitymyocardial infarctionHeart failurecardiac injury mortality myocardial infarction troponinCardiologybiology.proteincardiovascular systembusinessJournal of Medical Biochemistry
researchProduct

Studies to Elucidate the Mechanism of Cardio Protective and Hypotensive Activities of Anogeissus acuminata (Roxb. ex DC.) in Rodents

2020

Anogeissus acuminata (Roxb. ex DC.) is a folkloric medicinal plant in Asia

1Pharmaceutical Scienceacute myocardial infarction 3030204 cardiovascular system & hematologyPharmacologyCreatineAnalytical ChemistryNitric oxidelcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinevasorelaxant 4lcsh:Organic chemistryIn vivoDrug DiscoveryRenin–angiotensin systemleft ventricular hypertrophy 2Physical and Theoretical ChemistryCyclic guanosine monophosphate030304 developmental biology0303 health sciencesbiologyOrganic ChemistryAngiotensin-converting enzymehypotensivechemistryChemistry (miscellaneous)biology.proteinMolecular MedicineCreatine kinasehistopathology 6cardio relaxant 5Ex vivoMolecules
researchProduct

Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe

2020

We compared the ST elevation myocardial infarction (STEMI) incidence during COVID-19 pandemic (March 2020) to January-February 2020 and to same time period in earlier years 2017-2019 in five Nordic-Baltic tertiary centers. During 2017-2019, there were no marked differences in STEMI incidence between January, February and March. During 2020, there was an average drop of 32% in STEMI incidence in March. The isolation measures may decrease the risk for respiratory virus infection and contribute to the lower STEMI incidence and that we might benefit from firmer suggestions on hand hygiene and social distancing during flu season at least among high-risk individuals.

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)media_common.quotation_subject030204 cardiovascular system & hematologyScandinavian and Nordic CountriesTertiary Care Centers03 medical and health sciences0302 clinical medicineSt elevation myocardial infarctionHygieneRespiratory virus infectionPandemicFlu seasonMedicineHumanscardiovascular diseases030212 general & internal medicinemedia_commonRetrospective Studiesbusiness.industryIncidence (epidemiology)IncidenceCOVID-19Latvia3. Good healthsurgical procedures operativeST-elevation myocardial infarctionincidenceST Elevation Myocardial InfarctionbusinessCardiology and Cardiovascular MedicineDemography
researchProduct

TROMBECTOMIA INTRACORONARICA CON NeVA STENT RETRIEVER IN PAZIENTI AFFETTI DA SINDROME CORONARICA ACUTA: ESPERIENZA MULTICENTRICA FIRST-IN-MEN

2021

Acute Myocardial Infarction Coronary ThrombectomySettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock

2021

Background: We aimed to evaluate the effect of intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required i…

Acute coronary syndromemedicine.medical_specialtyacute coronary syndrome; cardiogenic shock; glycoprotein IIb/IIIa receptor inhibitors; myocardial infarction; percutaneous coronary interventionmedicine.medical_treatmentArticleacute coronary syndromeInternal medicineAngioplastyRisk of mortalityMedicineMyocardial infarctionAdverse effectbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseaseglycoprotein IIb/IIIa receptor inhibitorsmyocardial infarctionConventional PCICardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

Post-Infectious Myocardial Infarction: New Insights for Improved Screening

2019

Acute infection is suspected of involvement in the onset of acute myocardial infarction (MI). We aimed to assess the incidence, pathogenesis and prognosis of post-infectious MI. All consecutive patients hospitalized for an acute MI in coronary care units were prospectively included. Post-infectious MI was defined by a concurrent diagnosis of acute infection at admission. Type 1 MI (acute plaque disruption) or Type 2 MI (imbalance in oxygen supply/demand) were adjudicated according to the universal definition of MI. From the 4573 patients admitted for acute MI, 466 (10%) had a concurrent acute infection (median age 78 (66–85) y, 60% male), of whom 313 (67%) had a respiratory tract infection.…

Acute coronary syndromemedicine.medical_specialtylcsh:Medicine030204 cardiovascular system & hematologyType 2 myocardial infarctionelderlyArticleacute coronary syndromeSepsisPathogenesissepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicinepneumonia030212 general & internal medicineMyocardial infarctionbusiness.industryIncidence (epidemiology)lcsh:Rpulmonary tract infectionGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalinfectionPneumoniabusinessin-hospital mortalityJournal of Clinical Medicine
researchProduct

Cystatin C levels are decreased in acute myocardial infarction: Effect of cystatin C G73A gene polymorphism on plasma levels

2005

Background: Cystatin C is the most abundant protease inhibitor in the plasma. Low plasma levels have been found in patients with aortic aneurysms and they seem correlated with the extension of the aortic lesions in early aneurysms detected by ultrasonography. Methods: In this study, plasma levels of cystatin C have been investigated in patients with acute myocardial infarction (AMI), unstable angina and controls. The effect on plasma levels of the G73A polymorphism of the CST3 gene has been also evaluated. Results: Patients with acute myocardial infarction showed significantly lower levels of cystatin C compared to unstable angina and controls, but levels were nearly normal in a week after …

Acute myocardial infarctionCystatin CCoronary artery diseaseUnstable angina
researchProduct

TLR2 and age-related diseases: potential effects of Arg753Gln and Arg677Trp polymorphisms in acute myocardial infarction.

2008

ABSTRACT Inflammation is a key component of immune system. It is involved in both defense and pathophysiological events maintaining the dynamic homeostasis of host organism. Its function is controlled by innate immunity genes. Both their polymorphisms and environmental conditions give rise to different phenotypes in human population. Proinflammatory genotype may be beneficial in early life but not in old people. With advancing age, indeed, it increases the vulnerability and the intensity to inflammatory reactions responsible for the chronic inflammatory diseases, such as atherosclerosis and myocardial infarction (MI). Several studies have looked for detecting a genetic risk profile that mig…

AdultAgingSettore MED/09 - Medicina InternaGenotypePopulationMyocardial InfarctionInflammationPolymorphism Single NucleotideProinflammatory cytokineImmune systemGene FrequencyMedicineHumansMyocardial infarctioneducationSettore MED/04 - Patologia Generaleeducation.field_of_studyInnate immune systembusiness.industryMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareToll-Like Receptor 2TLR2Amino Acid SubstitutionItalyTLR2age-related diseasespolymorphismsacute myocardial infarction.PharmacogenomicsCase-Control StudiesImmunologyGeriatrics and Gerontologymedicine.symptombusinessRejuvenation research
researchProduct

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

2023

The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics,…

AdultAngiotensin Receptor AntagonistsAspirinHealth PolicyHumansAngiotensin-Converting Enzyme InhibitorsHospital MortalityRegistries03.02. Klinikai orvostanNon-ST Elevated Myocardial InfarctionCardiology and Cardiovascular Medicine
researchProduct

Myocardial infarction marker levels are influenced by prothrombin and tumor necrosis factor-α gene polymorphisms in young patients.

2012

Polymorphisms of genes encoding key factors for the control and activation of inflammatory response and coagulation cascade regulation may play a role in genetic susceptibility to acute myocardial infarction (AMI). This study sought to analyze the effect of TNF - 308G/A and pro-thrombin (FII) 20210G/A polymorphisms on the laboratory parameters of young patients affected by AMI. Results indicated that TNF - 308A positive genotype frequencies were increased in these patients and that a genetically determined higher production of TNF-alpha is associated in young subjects to a more severe cardiac damage as depicted by higher levels of troponin, Creatine kinase-MB Isoenzyme (mCK-MB) and a signif…

AdultMalePro-thrombinGenotypeImmunologyMyocardial InfarctionSNPSingle-nucleotide polymorphismAcute myocardial infarctionPolymorphism Single NucleotideBiochemistryYoung AdultGene FrequencyGenotypeTroponin IGenetic predispositionCreatine Kinase MB FormHumansImmunology and AllergyMedicineGenetic Predisposition to DiseaseMolecular BiologyAllele frequencyInflammationbiologyTumor Necrosis Factor-alphabusiness.industryAge FactorsFibrinogenHematologyMiddle AgedTroponinTumor necrosis factor-a.TroponinGenotype frequencyImmunologyHaematochemical parameterbiology.proteinProthrombinCreatine kinasebusinessBiomarkers
researchProduct